Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06912633 · ClinicalTrials.gov registry record · Phase 2
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
A Phase 2 study of Retinitis Pigmentosa, sponsored by jCyte.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 14
- Study locations
NCT06912633: Recruiting Phase 2 study of Retinitis Pigmentosa, sponsored by jCyte.
NCT06912633 is a Phase 2 study of Retinitis Pigmentosa that is actively recruiting participants, run by jCyte. The registered enrollment target is 60 participants, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (77% lower). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06912633, a Phase 2 study of Retinitis Pigmentosa, is actively recruiting participants, sponsored by jCyte.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (6.0M jCell) compared to sham-treated controls.
Primary Outcome
Assessed by treatment emergent adverse events, immunogenicity and safety visual assessments
Conditions Studied
Interventions
- BIOLOGICAL human retinal progenitor cells
- OTHER Mock injection
Study Locations (14)
California
- California Retina Consultants - Bakersfield
- Retina-Vitreous Associates Medical Group - Beverly Hills
- Gavin Herbert Eye Institute, UC Irvine - Irvine
- Retina Consultants Medical Group - Sacramento
- Bay Area Retina Associates - Walnut Creek
Texas
- Retina Consultants of Texas: Bellaire Retina Center - Bellaire
- Retina Consultants of Texas: San Antonio - San Antonio
Arizona
- Associated Retina Consultants - Phoenix
Florida
- Vitreo Retinal Associates - Gainesville
Georgia
- Georgia Retina - Marietta
Illinois
- Illinois Retina Associates - Oak Park
New Jersey
- NJRetina - Teaneck
New York
- Long Island Vitreoretinal Consultants - Westbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT06912633 shows while recruiting
NCT06912633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 2 interventions - of which human retinal progenitor cells is the first listed.
NCT06912633 lists 14 locations in 9 states (California, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT06912633 about?
NCT06912633 is a clinical study titled "Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)". This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatme...
What is the current status of trial NCT06912633?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-06-20. Estimated completion is 2026-09.
What conditions does trial NCT06912633 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT06912633?
The interventions under investigation include: human retinal progenitor cells (BIOLOGICAL), Mock injection (OTHER).
Who is sponsoring clinical trial NCT06912633?
This trial is sponsored by jCyte, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06912633 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06912633's enrollment target sits among peer trials
60 15th of 37 higher than 23 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
COMPLETED · Phase 2
-
Trial of Oral Valproic Acid for Retinitis Pigmentosa
COMPLETED · Phase 2
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI